AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.8 |
Market Cap | 978.13M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -73.22 |
PE Ratio (ttm) | -0.06 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.5 |
Volume | 5,734 |
Avg. Volume (20D) | 289,236 |
Open | 4.32 |
Previous Close | 4.30 |
Day's Range | 4.13 - 4.32 |
52-Week Range | 3.50 - 74.00 |
Beta | undefined |
About BDRX
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and ...
Analyst Forecast
According to 1 analyst ratings, the average rating for BDRX stock is "Buy." The 12-month stock price forecast is $200, which is an increase of 4650.59% from the latest price.